Ausgewählte Veröffentlichungen

Seit 2020

2024

M. Schlander:

Medizinischer Fortschritt im Zeichen von „Degrowth“?

Frankfurter Allgemeine Zeitung (06. Mai 2024), Wirtschaft, Standpunkt.

Wer eine „Postwachstumsgesellschaft“ fordert, sollte sagen, welche Konsequenzen dies für die Gesundheitsversorgung haben könnte. Ein Gastbeitrag.

M. Schlander, W. van Harten, V.P. Retèl, et al.:

The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions.

Lancet Oncology (2024), DOI: 10.1016/S1470-2045(23)00636-8 (Online-Version vorab verfügbar).

(Publikation auf Anfrage erhältlich)

M.W. Lwin, C.-Y. Cheng, S. Calderazzo, C. Schramm, M. Schlander:

Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis.

Front. Public Health (2024), DOI: 10.3389/fpubh.2024.1307427 (Online-Version vorab verfügbar).

2023

P.D. Pham, M. Schlander, R. Eckford, K. Hernandez-Villafuerte, J. Ubels:

Developing a Conceptual Framework for Socioeconomic Impact Research in European Cancer Patients: A ‘Best-Fit’ Framework Synthesis.

Patient (2023), DOI: 10.1007/s40271-023-00632-z (Online-Version vorab verfügbar).

D. Hernandez, S.A. Khan, M. Schlander:

Krankheitslast von Brustkrebs in Deutschland: Epidemiologie und Kosten.

Forum (2023), DOI: 10.1007/s12312-023-01216-6 (Online-Version vorab verfügbar).

(Publikation auf Anfrage erhältlich)

R. Schaefer, D. Hernández, T. Bärnighausen, P. Kolominsky-Rabas, M. Schlander:

The HTA-informed Decision-Making by GBA/IQWiG in Germany and NICE in England: The Role of Budget Impact.

Value in Health (2023), DOI: 10.1016/j.jval.2023.02.018 (Online-Version vorab verfügbar).

(Publikation auf Anfrage erhältlich)

D. Hernandez, C.-Y. Cheng, K. Hernandez-Villafuerte, M. Schlander:

Survival and comorbidities in lung cancer patients: evidence from administrative claims data in Germany.

Oncology Research (2022); 30(4), 173-185. DOI: 10.32604/or.2022.027262.

C.-Y. Cheng, C. Calderazzo, C. Schramm, M. Schlander:

Modeling the natural history and screening effects for colorectal cancer using both adenoma and serrated neoplasia pathways: the development, calibration, and validation of a discrete event simulation model.

MDM Policy & Practice (2023); 8(1). DOI: 10.1177/23814683221145701 (Online-Version vorab verfügbar).

S.A. Khan, K. Hernandez-Villafuerte, D. Hernandez, M. Schlander:

Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach.

Frontiers in Public Health (2023). DOI: 10.3389/fpubh.2022.946544.

2022

J. Schneider, D. Hernandez, M. Schlander, V. Arndt; on behalf of the CAESAR study group:

Out-of-pocket payments and loss of income among long-term breast cancer survivors in Germany: a multi-regional population-based study.

Journal of Cancer Survivorship (2022). DOI: 10.1007/s11764-022-01293-x (Online-Version vorab verfügbar).

V. Arndt, D. Hernandez, M. Schlander:

Einkommenseinbußen nach Krebs – Ergebnisse aus Deutschland.

Onkologie (2022), DOI: 10.1007/s00761-022-01243-3 (Online-Version vorab verfügbar).

(Publikation auf Anfrage erhältlich)

D. Hernandez, P. Giri, A. von Both, M. Schlander:

Krankheitslast von Lungenkrebs in Deutschland: Epidemiologie und Kosten.

Forum (2022), DOI: 10.1007/s12312-022-01123-2 (Online-Version vorab verfügbar).

(Publikation auf Anfrage erhältlich)

D. Hernandez, A. von Both, M. Schlander:

Krankheitslast von Prostatakrebs in Deutschland: Epidemiologie und Kosten.

Forum (2022), Ausgabe 3/2022.

(Publikation auf Anfrage erhältlich)

T. Muchadeyi Muchandifunga, K. Hernandez-Villafuerte, M. Schlander:

Quality appraisal for systematic literature reviews of health state utility values. A descriptive analysis.

BMC Medical Research Methodology (2022), DOI: 10.21203/rs.3.rs-1589412/v1 (Online-Version vorab verfügbar über Research Square).

(Publikation auf Anfrage erhältlich)

D. Hernandez, F. Wagner, K. Hernandez-Villafuerte, M. Schlander:

Economic Burden of Pancreatic Cancer in Europe: a Literature Review.

Journal of Gastrointestinal Cancer (2022). DOI: 10.1007/s12029-022-00821-3 (Online-Version vorab verfügbar).

M. Brougham, M. Schlander, H. Telser, H. Bakshi, O. Sola-Morales:

Use of the incremental cost effectiveness ratio for decision-making policies - what's the problem? A perspective paper.

Expert Review of Pharmacoeconomics & Outcomes Research (2022), DOI: 10.1080/14737167.2022.2064847 (Online-Version vorab verfügbar).

(Publikation auf Anfrage erhältlich)

M. Schlander, J. Richardson:

QALYs In Health Resource Usage Decisions.

Health Aff (Millwood) 2022; 41(4): 609-610. DOI: 10.1377/hlthaff.2021.01926.

J. Ubels, K. Hernandez-Villafuerte, M. Schlander:

The Value of Freedom: A Review of the Current Developments and Conceptual Issues in the Measurement of Capability.

Journal of Human Development and Capabilities (2022). DOI:10.1080/19452829.2022.2053506 (Online-Version vorab verfügbar).

J.W. März, A. Molnar, S. Holm, M. Schlander:

The Ethics of COVID-19 Vaccine Allocation: Don't Forget the Trade-Offs!

Public Health Ethics; phac001 (2022). DOI: 10.1093/phe/phac001 (Online-Version vorab verfügbar).

D. Moro, M. Schlander, H. Telser, O. Sola-Morales, M.D. Clark, A. Olaye, C. Camp, M. Jain, T. Butt, S. Bakshi:

Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2].

Expert Rev Pharmacoecon Outcomes Res. (2022). DOI: 10.1080/14737167.2022.2014324 (Open Access Artikel).

R.D. Eckford, A. Gaisser, V. Arndt, M. Baumann, E. Kludt, K. Mehlis, J. Ubels, E.C. Winkler, S. Weg-Rehmers, M. Schlander:

The COVID-19 Pandemic and Cancer Patients in Germany: Impact on Treatment, Follow-Up Care, and Psychological Burden.

Frontiers. Public Health 9: 788598 (2022). DOI: 10.3389/fpubh.2021.788598 (Open Access Artikel).

A. Gaisser, R.D. Eckford, V. Arndt, D. Doege, E. Kludt, J. Ubels, M. Schlander, S. Weg-Rehmers:

Fast zwei Jahre Coronapandemie aus der Perspektive von Krebsbetroffenen.

Onkologe 28, 248–252 (2022). DOI: 10.1007/s00761-022-01096-w (Open Access Artikel).

D. Hernandez, K. Hernandez-Villafuerte, M. Schlander:

Messung der Kosten von Krebserkrankungen in Deutschland. Teil 2 - Wirtschaftliche Belastung.

Forum 37, 42–48 (2022). DOI: 10.1007/s12312-021-01026-8.

M. Thong, D. Doege, L. Weißer, L. Koch-Gallenkamp, H. Bertram, A. Eberle, B. Holleczek, A. Nennecke, A. Waldmann, S.R. Zeissig, R. Pritzkuleit, M. Schlander, H. Brenner, V. Arndt:

Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study.

Journal of Cancer Research and Clinical Oncology (2022), 148(1), 155–162. DOI: 10.1007/s00432-021-03825-x (Open Access Artikel).

2021

D. Hernandez, K. Hernandez-Villafuerte, M. Schlander:

Messung der Kosten von Krebserkrankungen in Deutschland. Teil 1 - Epidemiologie und Krankheitslast.

Forum 36, 406–410 (2021). DOI: 10.1007/s12312-021-00988-z.

R. Schaefer, D. Hernandez, L. Selberg, M. Schlander:

Health technology assessment (HTA) in England, France and Germany: What do matched drug pairs tell us about recommendations by national HTA agencies?

J Comp Eff Res (2021). DOI: 10.2217/cer-2021-0047 (Online-Version vorab verfügbar).

J.W. März, S. Holm, M. Schlander:

Resource allocation in the Covid-19 health crisis: are Covid-19 preventive measures consistent with the Rule of Rescue?

Medicine, Health Care and Philosophy (2021). DOI: 10.1007/s11019-021-10045-0 (Online-Version vorab verfügbar).

M. Schlander, K. Hernandez-Villafuerte, C.-Y. Cheng, J. Mestre-Ferrandiz, M. Baumann:

How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment.

PharmacoEconomics (2021). DOI: 10.1007/s40273-021-01065-y (Online-Version vorab verfügbar).

C.-Y. Cheng, T. Datzmann, D. Hernandez, J. Schmitt, M. Schlander:

Do certified cancer centers provide more cost-effective care? A health economic analysis of colon cancer care in Germany using administrative data.

International Journal of Cancer (2021). DOI: 10.1002/ijc.33728 (Online-Version vorab verfügbar).

European Expert Group on Orphan Drug Incentives:

Orphan Medicine Incentives:
How to address the unmet needs of disease patients by transforming the European OMP landscape?

Copenhagen Economics (May 2021), Booklet.

D. Hernandez, M. Schlander:

Income loss after a cancer diagnosis in Germany: An analysis based on the socio-economic panel survey.

Cancer Medicine (2021), 10(11): 3726–3740.

S.A. Khan, K.V. Hernandez-Villafuerte, M.T. Muchadeyi, M. Schlander:

Cost-effectiveness of risk-based breast cancer screening: A systematic review.

International Journal of Cancer (2021). DOI: 10.1002/ijc.33593 (Online-Version vorab verfügbar).

2020

M. Schlander:

PRO ("patient-reported outcomes") und Lebensqualität in der Onkologie.

Forum (2020), 35: 382-390.

[Publikation auf Anfrage erhältlich]

Kommentare und Antworten zur nachstehenden Veröffentlichung von T. Ran, S.B. Eichmüller, P. Schmidt, M. Schlander:

1. Kommentare zu "Cost of decentralized CAR T-cell production in an academic nonprofit setting".

2. Antworten: Kommentare zu "Cost of decentralized CAR T-cell production in an academic nonprofit setting".

International Journal of Cancer (2020).

T. Ran, S.B. Eichmüller, P. Schmidt, M. Schlander:

Cost of decentralized CAR T-cell production in an academic nonprofit setting.

International Journal of Cancer (2020), 147(12): 3438-3445.

M. Schlander:

Allen Patienten gerecht werden - Gedanken eines Gesundheitsökonomen zur Covid-19-Krise.

Zeitungsartikel (Standpunkt) / Frankfurter Allgemeine Zeitung / Nr. 124, S. 20 (29.05.2020).

M. Schlander:

HTA agencies need evidence-informed deliberative processes:
Comment on “Use of evidence-informed deliberative processes by health technology assessment agencies around the globe".

Int J Health Policy Manag (2020). DOI: 10.34172/ijhpm.2020.22 [Online-Version vorab verfügbar].

J.M. Heard, C. Vrinten, M. Schlander, C.M. Bellettato, C. van Lingen, M. Scarpa; MetabERN collaboration group:

Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network.

Orphanet Journal of Rare Diseases, (2020) Jan 6; 15(1): 3.